On Friday, Canaccord Genuity adjusted its price target for Definitive Healthcare Corp (NASDAQ:DH), reducing it to $5.00 from the previous $6.00, while retaining a Hold rating on the stock. The firm's analysis is based on Definitive Healthcare's updated outlook for calendar year 2024 (CY24) and a preliminary view of calendar year 2025 (CY25). The company has revised its CY25 guidance, now forecasting flat growth at the midpoint, which is an improvement from the previously anticipated 1% decline. Furthermore, the Adjusted EBITDA margin is expected to be around 31%, signifying an enhancement from the former estimate of approximately 30%.
Definitive Healthcare's management has provided insights into the upcoming year, suggesting that the current -4% growth in committed remaining performance obligations (cRPO) could be indicative of the overall revenue trend for the next year. The company anticipates experiencing sequential revenue dips throughout the first half of 2025, with a recovery and sequential growth projected for the second half of the year.
The firm also shared expectations regarding profitability, with projections pointing to a contraction in the Adjusted EBITDA margin by at least a few hundred basis points. This anticipated decrease is attributed to the forecasted revenue declines during the first half of the year. Despite the lowered price target, the Hold rating indicates that Canaccord Genuity maintains a neutral stance on the stock's near-term performance.
In other recent news, Definitive Healthcare Corp has been the subject of multiple significant developments. The company's Q2 2024 financial results showed a 5% year-over-year increase in revenue to $63.7 million, exceeding their own projections. The adjusted EBITDA also surpassed expectations, marking a 21% YoY increase to reach $20.9 million. Despite these positive outcomes, the company faced challenges with customer acquisition and upsell, attributing the underperformance to macroeconomic conditions and sales execution issues.
In addition to financial results, the company announced the appointment of Kate Shamsuddin Jensen as the new Chief Operating Officer. Jensen, who has been with Definitive Healthcare since May 2024, will receive an annual base salary of $360,000 and is eligible for a performance-based cash bonus targeting 60% of her base salary. She has also been granted 113,379 time-vesting restricted stock units valued at $500,000.
On the analyst front, BTIG initiated coverage of Definitive Healthcare with a Buy rating, highlighting the company's strong financial performance, high margins relative to the healthcare IT sub-sector, and generation of significant free cash flow. The firm also noted that Q3 revenue is forecasted to dip by 4% to 7% compared to Q3 2023, and full-year 2024 revenue is predicted to range between $247 million and $251 million, according to the company's CEO, Kevin Coop.
InvestingPro Insights
To complement Canaccord Genuity's analysis, InvestingPro data provides additional context for Definitive Healthcare Corp's financial position. The company's market capitalization stands at $673.25 million, with a revenue of $255.85 million for the last twelve months as of Q3 2024. Despite the anticipated challenges, InvestingPro Tips highlight that net income is expected to grow this year, aligning with management's projection of improved performance in the latter half of 2025.
The company's P/E ratio (Adjusted) of 30.13 suggests investors are pricing in future growth expectations, even as the firm faces near-term headwinds. Notably, Definitive Healthcare operates with a moderate level of debt and maintains liquid assets that exceed short-term obligations, potentially providing financial flexibility during the projected revenue dips in early 2025.
InvestingPro Tips also indicate that management has been aggressively buying back shares, which could signal confidence in the company's long-term prospects despite the current growth challenges. For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips that could provide further insights into Definitive Healthcare's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.